| 2026 | Integrated CT-based assessment of muscle and adiposity for risk stratification in advanced pancreatobiliary cancer
| FRONTIERS IN NUTRITION |
| 2026 | Molecular and Phenotypic Characterization of Fluid-Derived Patient-Derived Cell and Organoid Models in Advanced Gastric Cancer
| JOURNAL OF GASTRIC CANCER |
| 2026 | Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial
| BMC CANCER |
| 2025 | Design and Synthesis of Boron-Containing Noncanonical Amino Acids With Enhanced Stability and Solubility
| EUROPEAN JOURNAL OF ORGANIC CHEMISTRY |
| 2025 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer
| ESMO OPEN |
| 2025 | Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial
| CANCER COMMUNICATIONS |
| 2024 | Discovery of selective LATS inhibitors via scaffold hopping: enhancing drug-likeness and kinase selectivity for potential applications in regenerative medicine | RSC MEDICINAL CHEMISTRY |
| 2024 | Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13) | CANCER RESEARCH AND TREATMENT |
| 2024 | A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17) | ESMO OPEN |
| 2024 | Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17). | Journal of Clinical Oncology |
| 2024 | A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study | ANTICANCER RESEARCH |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | Journal of Clinical Oncology |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response | CELL REPORTS MEDICINE |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis | Cancers |
| 2022 | A novel anti-cancer compound development targeting YAP-TEAD protein-protein interaction | European Journal of Cancer |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer | NATURE COMMUNICATIONS |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients | Genomics & Informatics |
| 2022 | Pre-treatment Nutritional Risk Assessment by NRS-2002 Predicts Prognosis in Patients With Advanced Biliary Tract Cancer: A Single Center Retrospective Study | Clinical Nutrition Research |
| 2022 | Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis | Cancers |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer | Experimental Cell Research |
| 2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial | Esmo Open |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer | Frontiers in Oncology |
| 2021 | Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer | CANCERS |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 2020 | Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients | FRONTIERS IN ONCOLOGY |
| 2020 | MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA |
| 2019 | Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors | 대한류마티스학회지 |
| 2019 | The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy | Nutrients |
| 2019 | Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2019 | HER2 Regulates Cancer Stem Cell Activities via the Wnt Signaling Pathway in Gastric Cancer Cells | ONCOLOGY |
| 2019 | Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer
| FRONTIERS IN ONCOLOGY |
| 2018 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
| BMC CANCER |
| 2018 | Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy
| FRONTIERS IN ONCOLOGY |
| 2018 | Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor | INTERNATIONAL JOURNAL OF CANCER |
| 2018 | Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study
| JOURNAL OF THORACIC DISEASE |
| 2017 | Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer | CANCER RESEARCH AND TREATMENT |
| 2017 | ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer | BRITISH JOURNAL OF CANCER |
| 2017 | Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
| ONCOLOGY LETTERS |
| 2017 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines | BIOCHEMICAL PHARMACOLOGY |
| 2017 | ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition | BIOCHEMICAL PHARMACOLOGY |
| 2017 | Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
| ANNALS OF SURGERY |
| 2016 | High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2016 | Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma.
| CANCER RESEARCH AND TREATMENT |
| 2014 | The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. | MOLECULAR CANCER THERAPEUTICS |
http://orcid.org/0000-0003-0952-3679
(6603306077)
